Lantern Pharma Raises $9.25M in Direct Offering, Plans AI Spinout
Event summary
- Lantern Pharma secures up to $9.25M in registered direct offering at $2.06 per share, with additional warrants.
- Concurrent private placement includes unregistered warrants for up to 2,135,923 shares at $2.27 exercise price.
- Company plans to spin out AI platform withZeta.ai into an independent entity, potentially listing it separately.
- Proceeds of $4.4M (before fees) earmarked for working capital and general corporate purposes.
- Closing expected May 14, 2026, subject to customary conditions.
The big picture
Lantern Pharma's move to spin out its AI platform reflects a broader trend in biotech, where companies seek to unlock separate valuations for their technology and drug development arms. The $9.25M raise, while modest, signals investor confidence in the AI-driven precision oncology space. The success of this strategy will hinge on whether withZeta.ai can attract dedicated funding and achieve market traction as an independent entity.
What we're watching
- AI Valuation
- Whether withZeta.ai can achieve higher valuation multiples as an independent entity.
- Execution Risk
- The pace at which Lantern Pharma can separate and list the AI business.
- Warrant Exercise
- How the potential $4.85M in additional proceeds from warrant exercises impacts liquidity.